XORTX Therapeutics Financials
XRTX Stock | 1.75 0.01 0.57% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 13.33 | 12.6987 |
|
|
XORTX | Select Account or Indicator |
Understanding current and past XORTX Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of XORTX Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in XORTX Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in XORTX Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of XORTX Therapeutics. Check XORTX Therapeutics' Beneish M Score to see the likelihood of XORTX Therapeutics' management manipulating its earnings.
XORTX Therapeutics Stock Summary
XORTX Therapeutics competes with Sernova Corp. XORTX Therapeutics is entity of Canada. It is traded as Stock on V exchange.Foreign Associate | USA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | Canada Stock View All |
Exchange | TSX Venture Exchange |
ISIN | CA98420Q2071 |
Business Address | 3710 33rd Street |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.xortx.com |
Phone | 403 455 7727 |
You should never invest in XORTX Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of XORTX Stock, because this is throwing your money away. Analyzing the key information contained in XORTX Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
XORTX Therapeutics Key Financial Ratios
There are many critical financial ratios that XORTX Therapeutics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that XORTX Therapeutics reports annually and quarterly.Return On Equity | -0.29 | ||||
EBITDA | (3.3 M) | ||||
Net Income | (2.16 M) | ||||
Book Value Per Share | 2.32 X | ||||
Market Capitalization | 5.64 M |
XORTX Therapeutics Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Net Tangible Assets | (484.1K) | 1.0M | 16.5M | 9.2M | 10.6M | 11.1M | |
Retained Earnings | (6.8M) | (8.0M) | (9.7M) | (19.2M) | (17.9M) | (17.0M) | |
Accounts Payable | 607.4K | 390.0K | 410.7K | 1.8M | 195.8K | 186.0K | |
Net Receivables | 9.0K | 11.3K | 40.4K | 81.8K | 60.7K | 36.9K | |
Total Current Assets | 815.2K | 2.1M | 20.2M | 14.8M | 4.1M | 6.7M | |
Total Assets | 1.1M | 2.3M | 22.0M | 12.3M | 5.5M | 8.2M | |
Cash | 58.6K | 171.3K | 18.9M | 10.4M | 3.4M | 6.1M | |
Total Liab | 1.3M | 1.0M | 5.3M | 5.4M | 825.9K | 784.6K | |
Net Invested Capital | (160.9K) | 1.3M | 16.7M | 7.0M | 4.6M | 5.5M | |
Net Working Capital | (484.5K) | 1.0M | 14.9M | 9.4M | 3.8M | 5.2M | |
Intangible Assets | 272.4K | 234.3K | 256.2K | 199.4K | 175.3K | 189.7K |
XORTX Therapeutics Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (201.4K) | 112.7K | 18.7M | (4.7M) | (7.0M) | (6.6M) | |
Depreciation | 19.9K | 20.4K | 17.9K | 75.3K | 139.7K | 146.7K | |
Net Income | (629.6K) | (1.3M) | (1.7M) | (9.5M) | (2.2M) | (2.3M) | |
End Period Cash Flow | 58.6K | 171.3K | 18.9M | 10.4M | 3.4M | 5.2M | |
Change To Netincome | 62.0K | 173.5K | (3.1M) | (4.5M) | (4.1M) | (3.9M) | |
Investments | (7.0K) | (14.4K) | (39.8K) | (44.2K) | (46.4K) | (48.7K) | |
Free Cash Flow | (256.6K) | (742.8K) | (6.1M) | (8.9M) | (6.6M) | (6.3M) | |
Other Non Cash Items | 1.6K | 846.0 | 75K | 3.7K | 3.3K | 3.2K |
XORTX Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining XORTX Therapeutics's current stock value. Our valuation model uses many indicators to compare XORTX Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across XORTX Therapeutics competition to find correlations between indicators driving XORTX Therapeutics's intrinsic value. More Info.XORTX Therapeutics is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . At this time, XORTX Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the XORTX Therapeutics' earnings, one of the primary drivers of an investment's value.XORTX Therapeutics Systematic Risk
XORTX Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. XORTX Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on XORTX Therapeutics correlated with the market. If Beta is less than 0 XORTX Therapeutics generally moves in the opposite direction as compared to the market. If XORTX Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one XORTX Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of XORTX Therapeutics is generally in the same direction as the market. If Beta > 1 XORTX Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
XORTX Therapeutics Other Current Liab Over Time
Today, most investors in XORTX Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various XORTX Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of XORTX Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
XORTX Therapeutics November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of XORTX Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of XORTX Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of XORTX Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing XORTX Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build XORTX Therapeutics's daily price indicators and compare them against related drivers.
Downside Deviation | 8.94 | |||
Information Ratio | 0.0578 | |||
Maximum Drawdown | 160.18 | |||
Value At Risk | (12.64) | |||
Potential Upside | 12.31 |
Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.